Navigation Links
MDS Pharma Services Launches Next Generation Phase I Study Management System
Date:7/7/2008

Proprietary ClinQuick(R) system builds on a 15-year track record of

technical leadership in early clinical research

KING OF PRUSSIA, PA, July 7 /PRNewswire-FirstCall/ - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, has launched the next generation of its proprietary ClinQuick(R) electronic system for Phase I study set-up, data capture, project tracking and personnel credential management. Aimed at improving client service, the new version of the ClinQuick(R) system extends a 15-year legacy of technical leadership in early clinical research. System enhancements include a more user-friendly interface, improved menu navigation and a more robust data platform. This new platform will enable faster and more flexible reporting and will ultimately allow clients to access their data via the internet.

"Since its implementation in 1993, ClinQuick(R) has been used successfully in more than 3,000 Phase I studies involving nearly 100,000 participants," said MDS Pharma Services President David Spaight. "Our investment to enhance the ClinQuick(R) system builds on that legacy of success and will allow us to meet growing client demand for early clinical research services while maintaining our leadership position in Phase I. This next-generation ClinQuick(R) system will further improve our ability to deliver high quality Phase I services on time."

About ClinQuick(R)

Designed and built by MDS Pharma Services for use in its Phase I clinical research centers, the fully integrated ClinQuick(R) system facilitates rapid data cleansing and client monitoring for seamless operation of both single and multi-site studies. ClinQuick(R) accelerates timelines, enables accurate direct data acquisition, and reduces costs by a third compared to traditional paper case report forms (CRFs) - the forms used by clients to collect and document data from each participating clinical research site. The system is fully CFR Part 11 compliant and can be used for study management and electronic data capture (EDC), either alone or in conjunction with a client-provided EDC system or paper CRFs. MDS Pharma Services offers one of the world's largest capacities for conducting early-phase clinical studies, with some 1,100 beds in five state-of-the-art clinical research facilities in North America and Europe.

About MDS Pharma Services

MDS Pharma Services is committed to delivering quality service on time. We offer a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, we apply advanced scientific and technological expertise throughout the drug discovery and development process - from lead optimization, pre-IND research, early clinical research (bioequivalence, phases I-IIa) and bioanalysis through to global clinical development (phases IIb-IV), central lab and centralized cardiac services. For more information, visit our website at http://www.mdsps.com.

MDS Pharma Services is a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ), a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,500 highly skilled people in 29 countries. Find out more at http://www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.


'/>"/>
SOURCE MDS Pharma Services
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Pekin, IL (PRWEB) , ... February 24, 2017 , ... ... in the 7th annual “Imagine Me Beyond What You See” body image mannequin art ... Professional’s Choice will be showcased and the winner revealed at the 31st annual iaedp ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... the Senior International Elite division on February 12th. Ms. Esparza qualified into ... the elite qualifier competition held in Las Vegas, Nevada. Frida is one of ...
(Date:2/23/2017)... ... ... The 89th Academy Awards will be celebrated this weekend, which means it’s ... Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” to the shoddiest ... for American Progress (CAP), for its report, Lessons From State Performance on NAEP: Why ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., ... From Not to Hot,” which will begin airing on February 24, 2017. The show ... from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series ...
(Date:2/23/2017)... Angeles, California (PRWEB) , ... February 23, 2017 ... ... Global Sports Development will host a diverse symposium on “Doping in ... of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb 24, 2017 ... Committee,s proposal for a new Board of Directors that ... The 2016-2017 Nomination Committee comprises representatives of the company,s ... quarter of 2016 who have accepted a seat on ... The composition of the 2016-2017 Nomination Committee was as ...
(Date:2/23/2017)... -- Visiomed, the French leader in medical grade ... the landscape of healthcare with their innovative use ... solutions. Recognizing the rising demand of self-monitoring alongside ... walls, Visiomed has launched BewellConnect, the most ground-breaking ... that is empowering the lives of patients. ...
(Date:2/23/2017)... 23. Februar 2017 LG Innotek hat heute ... Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... Bereich zwischen 200 und 280 nm und eignet sich damit ... es ihre DNA zerstört. Das Produkt von LG Innotek ... ...
Breaking Medicine Technology: